HOME >> MEDICINE >> NEWS
Drug combination slows progression of treatment resistant bone marrow cancer

CHAPEL HILL -- Combining a newly formulated drug with one that is already a standard treatment slows the progression of multiple myeloma, an advanced cancer of the bone marrow cells, according to a clinical trial led by a University of North Carolina at Chapel Hill School of Medicine researcher.

The phase III trial included 646 patients from 18 countries with relapsed or refractory multiple myeloma, a condition in which cancerous cells continue to multiply despite treatment. Patients in the trial were randomly assigned to receive the drug bortezomib (Velcade), standard therapy for relapsed multiple myeloma, or a combination of Velcade and Doxil, a chemotherapy drug (doxorubicin) delivered via liposomes, or microscopic fat bubbles.

An interim analysis of study participants who received the combination treatment showed a better response in the combination group than in participants who received standard treatment. The combination group's median time to progression - the time interval between the response to treatment and the time the disease starts to show evidence of growing or recurring - was 9.3 months, while those on Velcade alone progressed after 6.5 months.

The three-month improvement is an important step forward in treatment for multiple myeloma, said Dr. Robert Orlowski, Lenvel Lee Rothrock associate professor in the department of hematology/oncology at the School of Medicine, and a member of the UNC Lineberger Comprehensive Cancer Center.

Orlowski presented the trial's early results on Monday (Dec. 11), at the meeting of the American Society of Hematology in Orlando, Fla. The study was supported by Johnson & Johnson, which owns Ortho Biotech, the maker of Doxil, and also has a financial interest in Velcade.

"The data for time to progression were so positive and encouraging that we decided to announce this information earlier than anticipated so more people could be aware of the benefits of this combination,
'"/>

Contact: L. H. Lang
llang@med.unc.edu
919-843-9687
University of North Carolina School of Medicine
12-Dec-2006


Page: 1 2

Related medicine news :

1. Phase II study shows combination improves survival of metastatic melanoma patients
2. Certain combination therapy found more effective for treating malaria in African children
3. To get blood pressure under control, combination of medicines may be best
4. Drug/intervention combinations offer benefit in severe CVD
5. Scripps research combination therapy obliterates new vessel growth in tumors and retinopathy
6. Drug combination proves effective against myeloma in Phase I trial
7. Drug combination could reduce risk of severe asthma attacks
8. Transplant patients keep their new kidney longer with a CellCept-based drug combination
9. Rheumatoid arthritis patients can benefit from Enbrel in combination with methotrexate
10. New combination therapy after surgery improves survival for pancreatic cancer patients
11. International study launched testing new drug combination to cut cardiovascular disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/19/2020)... (PRWEB) , ... March 19, 2020 , ... Therapies of ... family in this time of crisis. TOTR welcome new telepractice patients across the country, ... info@therapiesotr.com or call 303-888-4840 to begin or resume your services safely! , Therapies ...
(Date:3/19/2020)... ... March 19, 2020 , ... Van Dyk Health Care, ... Family of Caring, on October 3, 2018 and is not involved in the operations ... news involving Family of Caring at Montclair. , “We are devastated to learn about ...
(Date:3/16/2020)... ... 2020 , ... To avoid the potential spread of coronavirus ... implementing several new universal health and safety measures agency-wide. , "Our top ... Monteic A. Sizer, executive director of Northeast Delta. "Extensive discussion has occurred around ...
(Date:3/15/2020)... ... March 14, 2020 , ... ... the Coronavirus (COVID-19) pandemic, National HouseCheck Corporation (‘HouseCheck’) is bringing their world-class ... employees. HouseCheck has launched its nationwide Virus Remediation and Decontamination program (the ...
(Date:3/13/2020)... , ... March 13, 2020 , ... ... training standards that require helping professionals to meet a baseline of new educational ... development, recruiting and consulting services for ABA organizations, has developed web-based training programs ...
Breaking Medicine News(10 mins):
(Date:3/20/2020)... ... March 20, 2020 , ... New Alliance Academy provides its ... life, as well as encourages those interested in pursuing tertiary studies to achieve their ... adolescents who attend the school have a good chance of progressing into college. , ...
(Date:3/16/2020)... (PRWEB) , ... March 16, ... ... WeInfuse has now integrated with six medical billing and Electronic Health Record ... WellSky’s Ascend and R2 Health. Multiple other EHR integrations are underway, including ...
(Date:3/16/2020)... ... 2020 , ... The American Academy of Allergy, Asthma & ... MSPH, FAAAAI. , The AAAAI is the largest professional membership organization for ... interest in the research and treatment of allergic and immunologic diseases, including asthma. ...
Breaking Medicine Technology:
Cached News: